So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
So-Young International Inc.NASDAQ: SY
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 15.7% from a year ago
Total equity stood at CN¥1.6B at the end of Q1 FY2026, down 15.7% from a year earlier and down 4.0% from the prior quarter. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Total equity amounted to 60.4% of total assets at the end of Q1 FY2026, down 11.5 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
CNY · from the balance sheet
- Latest · FY2025
- 1.67B CNY
- Year-over-year change
- -14.7%
- 4-year CAGR
- -9.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.67B | -14.7% |
| FY2024 | 2024-12-31 | 1.96B | -23.5% |
| FY2023 | 2023-12-31 | 2.56B | -1.8% |
| FY2022 | 2022-12-31 | 2.61B | +3.6% |
| FY2021 | 2021-12-31 | 2.52B | — |
Total Equity vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -15.7% is the 7th highest of 11, against a peer median of -2.1%.
- Total equity amounts to 60.4% of total assets for SY, versus a peer median of 60.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CN¥1.6B CNY | -15.7% | -13.8% | 60.4% | |
| Mar 2026 | $889.02M USD | +666.6% | — | 33.8% | |
| Mar 2026 | $561.12M USD | +23.4% | — | 87.8% | |
| Apr 2026 | $488.1M USD | -13.4% | -3.8% | 44.8% | |
| Mar 2026 | $366.17M USD | -33.6% | -8.6% | 90.9% | |
| Mar 2026 | $202.86M USD | +64.9% | -2.8% | 75.5% | |
| Feb 2026 | $133.77M USD | -29.4% | -11.2% | 91.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M USD | -69.0% | — | 45.9% |
| Mar 2026 | $45.69M USD | -46.6% | -38.2% | 29.1% | |
| Mar 2026 | -$63.33M USD | +70.3% | — | 22.1% | |
| Mar 2026 | -$216.38M USD | +9.2% | — | 74.2% | |
| Peer median (excluding SY) | — | -2.1% | -8.6% | 60.1% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.33B | 694.42M | 426.12M | 587.75M | 483.2M |
| Short-term Investments | 408.95M | 875.96M | 900.82M | 599.04M | 453.76M |
| Net Receivables | 110.45M | 170.29M | 80.38M | 226.25M | 68.65M |
| Inventory | 91.81M | 120.48M | 118.92M | 151.75M | 233.54M |
| Other Current Assets | 18.19M | 17.29M | 147.45M | 159.56M | 246.39M |
| Total Current Assets | 2.03B | 1.92B | 1.72B | 1.72B | 1.49B |
| Property, Plant & Equipment (Net) | 220.19M | 179.08M | 235.19M | 318.12M | 545.54M |
| Goodwill | 540.69M | 540.69M | 540.69M | 684K | 684.43K |
| Intangible Assets | 193.96M | 169.28M | 145.25M | 126.62M | 144.19M |
| Long-term Investments | 252.5M | 227.96M | 261.02M | 280.28M | 274.93M |
| Tax Assets | 47.52M | 64.74M | 78.03M | 84.95M | 69.36M |
| Other Non-current Assets | 48.1M | 99.29M | 310.49M | 285.1M | 131.08M |
| Total Non-current Assets | 1.3B | 1.28B | 1.49B | 1.01B | 1.17B |
| Total Assets | 3.33B | 3.2B | 3.21B | 2.74B | 2.65B |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 29.83M | 69.77M | 39.81M |
| Tax Payables | 48.57M | 74.58M | 56.89M | 0 | 0 |
| Deferred Revenue | 190.26M | 181.67M | 195.21M | 190.37M | 292.65M |
| Other Current Liabilities | 256.23M | 239.93M | 288.77M | (119.6M) | 276.34M |
| Total Current Liabilities | 712.4M | 538.04M | 540.42M | 630.21M | 784.55M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 38.58M | 30.99M | 25.08M | 19.76M | 10.62M |
| Deferred Revenue (Non-current) | (38.58M) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 38.58M | 30.99M | 1.54M | 1.26M | 2.78M |
| Total Non-current Liabilities | 100.93M | 51.97M | 112.83M | 146.22M | 196.89M |
| Total Liabilities | 813.33M | 590.01M | 653.25M | 776.43M | 981.44M |
| Common Stock | 267K | 273K | 275K | 290K | 294.19K |
| Retained Earnings | (272.37M) | (346.62M) | (330.17M) | (885.84M) | (1.18B) |
| Accumulated OCI | (63.56M) | 33.13M | 52.04M | 31.56M | 59.83M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 70.85M | 109.94M | 117.19M | 119.61M | 115.58M |
| Total Equity | 2.52B | 2.61B | 2.56B | 1.96B | 1.67B |
| Total Debt | 105.89M | 71.26M | 145.77M | 239.88M | 299.9M |
| Net Debt | (1.23B) | (623.16M) | (280.35M) | (347.87M) | (183.3M) |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.